{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:07:11Z","timestamp":1788869231340,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":765,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"medical editorial assistance was provided by Novartis Pharmaceuticals Corporation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jbo.2012.07.002","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T00:16:15Z","timestamp":1344644175000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer"],"prefix":"10.1016","volume":"1","author":[{"given":"Peyman","family":"Hadji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Ziller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Autenrieth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Muth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Ruebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Birkholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erhardt","family":"Diebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Gleissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen E.","family":"Gschwend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2012.07.002_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.jbo.2012.07.002_bib2","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"European Urology"},{"key":"10.1016\/j.jbo.2012.07.002_bib3","unstructured":"Novartis Pharmaceuticals Corporation. Zometa (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011."},{"key":"10.1016\/j.jbo.2012.07.002_bib4","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.07.002_bib5","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.jbo.2012.07.002_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.jbo.2012.07.002_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.jbo.2012.07.002_bib8","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.jbo.2012.07.002_bib9","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2010.12.006","article-title":"Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid","volume":"59","author":"Jung","year":"2011","journal-title":"European Urology"},{"key":"10.1016\/j.jbo.2012.07.002_bib10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2012.07.002_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2012.07.002_bib12","unstructured":"Body J-J, Cook RJ, Costa L, Brown JE, Terpos E, Saad F., et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Poster Presented at The IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, October 28\u201331, 2009."},{"key":"10.1016\/j.jbo.2012.07.002_bib13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.jbo.2012.07.002_bib14","unstructured":"Ibrahim T, Mercatali L, Sacanna E, Ricci R, Scarpi E, Serra P., et al. Circulating levels of RANK\/RANKL and OPG in patients with bone metastasis treated with zoledronic acid: a prospective study. Poster Presented at 2011 ASCO Annual Meeting, Chicago, IL, June 3\u20137; 2011."},{"key":"10.1016\/j.jbo.2012.07.002_bib15","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1158\/1078-0432.CCR-03-0735","article-title":"Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer","volume":"10","author":"Michaelson","year":"2004","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.jbo.2012.07.002_bib16","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0090-4295(02)02583-9","article-title":"Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer","volume":"61","author":"Noguchi","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.jbo.2012.07.002_bib17","doi-asserted-by":"crossref","unstructured":"Saad F, Segal S, Eastham J. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. European Urology 2012 Epub ahead of print. doi:10.1016\/j.eururo.2012.05.007","DOI":"10.1016\/S1569-9056(12)60915-4"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213741200022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221213741200022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:11Z","timestamp":1761941711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221213741200022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S221213741200022X"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2012.07.002","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2012.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier GmbH","name":"copyright","label":"Copyright"}]}}